Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

cGMP via PKG activates 26S proteasomes and enhances degradation of proteins, including ones that cause neurodegenerative diseases

Proceedings of the National Academy of Sciences(2020)10.1073/pnas.2003277117Source: DataRank Database

cGMP via PKG activates 26S proteasomes and enhances degradation of proteins, including ones that cause neurodegenerative diseases is a research paper published in Proceedings of the National Academy of Sciences (2020). On theSindex it has a DataRank of 0. It has been cited 100 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access100 citations

Download PDF

Cite:

Linked data & code

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)Impact (FWCI 4.48)OA: hybridTopics (60)Linked Datasets (8)DataCite Reuse (8)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (5)

Sylwia D. Tyrkalska ORCID,Angeleen Fleming ORCID,David C. Rubinsztein ORCID,Alfred L. Goldberg ORCID,Jordan J. S. VerPlank ORCID

Live enrichment

PubMed:32513741 PMC:PMC7321992 OpenAlex:https://openalex.org/W3032905932

NIGMS NIH HHS

Grant: F32 GM128322

Medical Research Council

Grant: UKDRI-2002

NIGMS NIH HHS

Grant: R01 GM051923

European Commission

Grant: 746509

Generation of new zebrafish models for the study of the pathogenesis of Huntington´s disease and for the identification of new therapeutic targets.

National Institutes of Health

Grant: 3R01GM051923-14S1

Molecular Chaperones and Protein Degradation

National Institutes of Health

Grant: 1F32GM128322-01A1

Enhancement of Protein Breakdown through PKG-mediated Phosphorylation of the Proteasome

FWCI

4.48

Citation Percentile

1.0%

Citation Trend

2020

2021

2022

2023

2024

2025

2026

hybridLicense: cc-by

journalhttps://www.pnas.org/content/pnas/117/25/14220.full.pdf

publisherhttps://www.pnas.org/content/pnas/117/25/14220.full.pdf

publisherhttp://www.pnas.org/syndication/doi/10.1073/pnas.2003277117

publisherhttps://pnas.org/doi/pdf/10.1073/pnas.2003277117

journalhttps://doi.org/10.1073/pnas.2003277117

Fields of Study

Ubiquitin and proteasome pathwaysGenetics and Neurodevelopmental DisordersCellular transport and secretion0301 basic medicine03 medical and health sciences0303 health sciences

MeSH Terms

Cyclic AMPAnimalsDisease Models, AnimalCyclic GMPHumansPhosphorylationZebrafishtau ProteinsCyclic AMP-Dependent Protein KinasesCyclic GMP-Dependent Protein KinasesNeurodegenerative DiseasesTauopathiesUbiquitinAnimals, Genetically ModifiedProteasome Endopeptidase ComplexUbiquitinationUbiquitinated ProteinsProteolysis

Keywords

ProteasomeCell biologyProtein kinase AProtein degradationCytosolProteolysisPhosphodiesteraseUbiquitincGMP-dependent protein kinasePhosphodiesterase 3BiologyPDE10AChemistryPhosphorylationBiochemistryMitogen-activated protein kinase kinaseEnzymecGMPProtein Kinase GProteasome PhosphorylationProteasome Endopeptidase Complextau ProteinsAnimals, Genetically ModifiedCyclic AMPCyclic GMP-Dependent Protein KinasesAnimalsHumansCyclic GMPZebrafishUbiquitinationNeurodegenerative DiseasesBiological SciencesCyclic AMP-Dependent Protein KinasesUbiquitinated ProteinsDisease Models, AnimalTauopathies

Sustainable Development Goals

SDG 3: 3. Good health

Additional file 1 of EYA2 suppresses the progression of hepatocellular carcinoma via SOCS3-mediated blockade of JAK/STAT signaling

10.6084/m9.figshare.14691867.v1figshare

Additional file 1 of EYA2 suppresses the progression of hepatocellular carcinoma via SOCS3-mediated blockade of JAK/STAT signaling

10.6084/m9.figshare.14691867figshare

Additional file 3 of EYA2 suppresses the progression of hepatocellular carcinoma via SOCS3-mediated blockade of JAK/STAT signaling

10.6084/m9.figshare.14691873.v1figshare

Additional file 3 of EYA2 suppresses the progression of hepatocellular carcinoma via SOCS3-mediated blockade of JAK/STAT signaling

10.6084/m9.figshare.14691873figshare

Additional file 1 of Phosphodiesterase 5 inhibitor mirodenafil ameliorates Alzheimer-like pathology and symptoms by multimodal actions

10.6084/m9.figshare.20279180.v1figshare

Additional file 1 of Phosphodiesterase 5 inhibitor mirodenafil ameliorates Alzheimer-like pathology and symptoms by multimodal actions

10.6084/m9.figshare.20279180figshare

Additional file 2 of EYA2 suppresses the progression of hepatocellular carcinoma via SOCS3-mediated blockade of JAK/STAT signaling

10.6084/m9.figshare.14691870.v1figshare

Additional file 2 of EYA2 suppresses the progression of hepatocellular carcinoma via SOCS3-mediated blockade of JAK/STAT signaling

10.6084/m9.figshare.14691870figshare